PubMed Health⌕ Search

PubMed · 15818174

Bladder cancer.

Abstract

PURPOSE OF REVIEW: This article reviews the recent literature concerning important issues in the management of patients with bladder cancer. A brief overview of all aspects of bladder cancer including the etiology, diagnosis, and treatment are discussed with a focus on recent advances. RECENT FINDINGS: Bladder cancer is a significant cause of morbidity and mortality. The treatment for bladder cancer should be based on individual patient risk assessment and should include a multidisciplinary approach. In patients with superficial bladder cancer, research has focused on improving and optimizing intravesical therapy to reduce tumor recurrence and progression as well as on methods to better select the most appropriate treatment for patients with high-risk features. The important prognostic and therapeutic role of lymphadenectomy during radical cystectomy has become apparent and recent work has attempted to better define what should be considered the standard for lymph node dissection. Finally, in an attempt to improve survival, advances have been made using systemic chemotherapy in both the perioperative settings as well as for treatment of metastatic bladder cancer. SUMMARY: Research continues to improve our understanding of bladder cancer. This ongoing investigation is currently being translated to the bedside with refinements in the diagnosis and treatment of patients with bladder cancer.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Lester S Borden, Peter E Clark, M Craig Hall. 2005. Bladder cancer.. https://doi.org/10.1097/01.cco.0000156985.47984.9e

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Impact of pre-operative MRI-measured membranous urethral length on urinary continence after radical cystectomy and orthotopic substitution: clinical and urodynamic evaluation.

PURPOSE: We aimed to determine the impact of membranous urethral length as measured by preoperative magnetic resonance imaging (MRI) upon continence following radical cystectomy and orthotopic substitution. MATERIALS AND METHODS: A total of 40 male patients (mean age 55.7 +/- 7 years) were subjected to radical cystectomy and orthotopic ileal substitution for bladder cancer. Membranous urethral length was measured by preoperative MRI utilizing coronal oblique high resolution T2 weighted images. In all evaluable patients, day and night continence statuses as well as time to stable continence were recorded. Urodynamic assessment included medium fill pouchometry and urethral pressure profilometry. RESULTS: Of all patients 10 were non-evaluable. Mean follow-up period was 8.1 +/- 1.9 months. All the evaluable patients were continent by daytime. On the other hand, 13 were continent by night (43.3%), 13 showed occasional enuresis (43.3%) and 4 were nightly enuretic (13.4%). Mean membranous urethral lengths were 14 +/- 1.9, 13.8 +/- 1.9 and 12.8 +/- 1.7 mm in the three groups, respectively (P = 0.51). Mean time to reach stable postoperative daytime continence was 5.4 +/- 4.6 whilst it was 12.5 +/- 7.4 weeks for nighttime continence. There was no significant correlation between preoperative membranous urethral length and time to stable day or night continence (R = -0.11, -0.08, respectively). Moreover, such correlation was not observed with postoperative urethral pressure profilometry parameters including maximum urethral pressure, maximum urethral closure pressure or functional urethral length (R = -0.33, -0.38, -0.16, respectively). CONCLUSION: Preoperative MRI-measured membranous urethral length has no value for judgment of postoperative continence status following radical cystectomy and ileal bladder substitution.

Cystectomy↗

Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments.

Bladder cancer is a heterogeneous disease. Non-muscle-invasive bladder cancer embraces a spectrum of tumors with varying degrees of clinical behavior. Transurethral resection remains the surgical mainstay for the treatment of non-muscle-invasive bladder cancer. In an attempt to decrease the recurrence or progression rate, intravesical chemotherapy or immunotherapy is also used. Radical cystectomy with bilateral pelvic lymph node dissection remains the gold standard for treating muscle-invasive bladder cancer. Over the last decade, the orthotopic neobladder has gained widespread popularity as the preferred mode of urinary diversion in both males and females with similar oncologic and functional outcomes. Well-designed trials with effective chemotherapy have shown a beneficial role for neoadjuvant chemotherapy.

Cystectomy↗